These insights pave the way for repurposing existing of new use of old antiandrogens like flutamide and employing estrogen receptor beta agonists in colorectal cancer treatment strategies, highlighting a potential shift in therapeutic approaches. This evidence concerns the gene ESR2 and colorectal cancer.